Register Now - Every Drop Matters: Reducing Product Loss in Sterile Filtration
Feature|Videos|December 17, 2025

Develop Your Biologic with Technology, Process Strategy, and Market Strategy in Mind

Biopharmaceutical manufacturers can strategically choose between fed-batch and continuous manufacturing to balance scalability, flexibility, and market demand across the product lifecycle.

Key Objectives

  • Understand how fed-batch and continuous manufacturing strategies align with differ
  • Identify the regulatory, operational, and organizational considerations that influence the transition between fed-batch and continuous bioprocessing.
  • Evaluate how continuous manufacturing can enhance responsiveness to market demand.

Early-phase clinical programs typically rely on fed-batch manufacturing, but growing confidence in continuous processing is enabling companies to plan long-term supply strategies earlier in development. Continuous manufacturing is well suited for unstable molecules, perfusion processes, and mid-scale production where agility, market responsiveness, and productivity gains are critical. Fed-batch remains dominant at very large scales. Charles Heise, Associate Director, Bioprocess Strategy & Development, at FUJIFILM Biotechnologies, explains that the main barriers to broader adoption are not technical limitations but regulatory planning, operational experience, and industry confidence. He also highlights the importance of working with experienced, innovation-driven CDMO partners.


Related to this article

The BioPharm Brief: A Matrix-Targeting ADC in Head and Neck Cancer, an RNAi Approval in Myasthenia Gravis, and AbbVie Bets on AND-Gated Bispecifics
Pyxis Oncology’s EDB+FN-targeting ADC micvotabart pelidotin shows a 39% confirmed response rate in previously treated head and neck cancer, FDA approves Regeneron and Alnylam’s cemdisiran (Livsayis) as the first RNAi therapy for generalized myasthenia gravis, and AbbVie partners with DISCO Pharmaceuticals on AND-gated bispecifics for solid tumors.
The BioPharm Brief: A First for Streamlined Biosimilar Approval, a Head-to-Head Bispecific Trial in Wet AMD, and In Vivo KIR-CAR T
Biocon’s pertuzumab biosimilar Pebrilzo becomes the first biosimilar approved under EMA’s tailored clinical approach, Visara doses the first patient in a phase 2b trial comparing its VEGF-A/ANG-2 bispecific VIS-101 with aflibercept in wet AMD, and Verismo Therapeutics licenses Stanford’s PACK-IT technology for in vivo KIR-CAR T therapies.